Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biohaven Pharmaceutical Holding Company Ltd (BHVN)

Biohaven Pharmaceutical Holding Company Ltd (BHVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Biohaven Highlights Neuroscience Advancements with 22 Presentations at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 22 abstracts, including three oral presentations, were accepted at the 2021 American Academy of Neurology...

BHVN : 72.58 (-2.45%)
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Stock Jumps 8.5%: Will It Continue to Soar?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest...

BHVN : 72.58 (-2.45%)
Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT

, /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today...

BHVN : 72.58 (-2.45%)
Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line Apparel Honor Fallen Service Members

, /PRNewswire/ -- Rick Ware Racing announced today its partnership with Biohaven's Nurtec® ODT (rimegepant) and Nine Line Apparel to honor the nation's fallen service members during the Memorial Day...

BHVN : 72.58 (-2.45%)
Biohaven Enrolls First Patient in Phase 2/3 Trial of Oral Zavegepant, Prompting $100 Million Milestone Funding Payment from Royalty Pharma

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: ), a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative,...

BHVN : 72.58 (-2.45%)
Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial–stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of...

BHVN : 72.58 (-2.45%)
Biohaven Announces Proposed Public Offering Of Common Shares

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative,...

BHVN : 72.58 (-2.45%)
Biohaven Announces Completion Of 50% Enrollment Ahead Of Timelines In Verdiperstat Pivotal HEALEY ALS Platform Trial At Massachusetts General Hospital

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") announced today that more than 50% of participants have been enrolled in the verdiperstat regimen...

BHVN : 72.58 (-2.45%)
Cassava Sciences (SAVA) Up More Than 600% YTD: Here's Why

Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, simufilam.

BIIB : 267.40 (-1.08%)
CPRX : 4.37 (-1.58%)
BHVN : 72.58 (-2.45%)
SAVA : 33.83 (-2.93%)
Biohaven's NURTEC® ODT Approved In Israel For Acute Treatment Of Migraine

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") and Medison Pharma announced today that NURTEC® ODT (rimegepant) was approved by the Israeli Ministry of Health for...

BHVN : 72.58 (-2.45%)
Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

LLY : 189.67 (+0.22%)
AMGN : 255.95 (+0.09%)
ABBV : 108.44 (+0.49%)
BHVN : 72.58 (-2.45%)
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue Estimates

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -25.26% and 0.30%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies...

BHVN : 72.58 (-2.45%)
Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments

, March 1, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage...

BHVN : 72.58 (-2.45%)
Biohaven Pharmaceutical Holding Co. Ltd. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March...

BHVN : 72.58 (-2.45%)
Biohaven To Report Fourth Quarter And Full Year 2020 Financial Results And Recent Business Developments On March 1, 2021

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological...

BHVN : 72.58 (-2.45%)
Why Biohaven (BHVN) Might Surprise This Earnings Season

Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BHVN : 72.58 (-2.45%)
Biohaven's BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced...

BHVN : 72.58 (-2.45%)
Cassava (SAVA) Rises on Late-Stage Alzheimer's Study Plans

Cassava (SAVA) provides outline for future study plans on its Alzheimer's disease candidate, simufilam.

BIIB : 267.40 (-1.08%)
PFE : 38.82 (+0.65%)
BHVN : 72.58 (-2.45%)
SAVA : 33.83 (-2.93%)
Biohaven Provides Update On ESG Practices

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates today...

BHVN : 72.58 (-2.45%)
Cassava (SAVA) Soars on Encouraging Alzheimer's Study Data

Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.

BIIB : 267.40 (-1.08%)
PFE : 38.82 (+0.65%)
BHVN : 72.58 (-2.45%)
SAVA : 33.83 (-2.93%)

Barchart Exclusives

Crude Oil Bounces Higher- The Correction Finds A Bottom
April 20 is the first anniversary of crude oil’s plunge to under negative $40 per barrel. On March 8, crude oil rose to a new high and then corrected. However, the bullish trend remains intact, with the price over $100 per barrel high in April 2021 than at the lows in April 2020. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar